sTREM2 and cerebral blood flow in White Matter Hyperintensity Patients: Associations with Cognitive Impairment
DOI:
https://doi.org/10.71321/xbcvcf98Keywords:
Keywords: Soluble triggering receptor expressed on myeloid cells 2, White matter hyperintensities, cerebral blood flow , Cognitive impairmentAbstract
Background: White matter hyperintensities (WMHs) are common neuroimaging markers of cerebral small vessel disease (CSVD) and are strongly associated with cognitive impairment. While cerebral hypoperfusion and neuroinflammation are recognized as major contributors to WMH pathology, the interplay between inflammatory biomarkers and cerebral blood flow (CBF) remains poorly understood. Soluble triggering receptor expressed on myeloid cells 2 (sTREM2), a marker of microglial activation, may play a dual role in neuroinflammation and vascular dysfunction.
Methods: A total of 138 participants aged 50–80 years were enrolled, including 75 individuals in WMH group and 63 individuals in healthy control (HC) group. All subjects underwent magnetic resonance imaging (MRI) including arterial spin labeling(ASL) for CBF quantification and neuropsychological assessments. Serum sTREM2 levels were measured. Group comparisons, logistic regression, and partial correlation analyses were performed to explore associations among sTREM2, CBF, and cognitive performance.
Results: Compared to HC group, serum sTREM2 levels were significantly elevated in the WMH group (P = 0.036), and gray matter(GM) CBF was significantly lower (P = 0.038). Logistic regression identified sTREM2 (OR = 1.041, P = 0.006) and age (OR = 1.081, P = 0.018) as independent risk factors for WMHs. Partial correlation analyses revealed a positive association between sTREM2 and gray matter CBF in healthy controls, but a negative association in the WMH group. Additionally, GM CBF was positively correlated with global cognitive scores (MMSE, MoCA) and executive function (Stroop Test C) in the WMH group.
Conclusion: Our findings suggest that higher serum sTREM2 levels and reduced brain perfusion may be closely linked to the presence and progression of white matter hyperintensities and associated cognitive decline. Notably, the direction of the relationship between sTREM2 and perfusion appears to vary by disease status, indicating a possible shift from compensatory to harmful inflammation. These results highlight the clinical value of combining inflammatory markers and perfusion imaging in identifying individuals at higher risk of small vessel-related cognitive impairment and may provide useful targets for early intervention and monitoring.
References
[1] Shi Y, Toga AW. Connectome imaging for mapping human brain pathways. Mol Psychiatry. 2017;22(9):1230–1240. https://doi.org/10.1038/mp.2017.92
[2] Zotin MCZ, Sveikata L, Viswanathan A, Yilmaz P. Cerebral small vessel disease and vascular cognitive impairment: from diagnosis to management. Curr Opin Neurol. 2021;34(2):246–257. https://doi.org/10.1097/WCO.0000000000000913
[3] Mu R, Qin X, Guo Z, Meng Z, Liu F, Zhuang Z, et al. Prevalence and consequences of cerebral small vessel diseases: a cross-sectional study based on community people plotted against 5-year age strata. Neuropsychiatr Dis Treat. 2022;18:499–512. https://doi.org/10.2147/NDT.S352651
[4] Markus HS, de Leeuw FE. Cerebral small vessel disease: recent advances and future directions. Int J Stroke. 2023;18(1):4–14. https://doi.org/10.1177/17474930221144911
[5] Quinn TJ, Makin S, Doubal F, Staals J. Cerebral small vessel disease and vascular cognitive impairment. In: Touyz RM, Delles C, editors. Textbook of Vascular Medicine. Cham: Springer; 2019. p. 449–459. https://doi.org/10.1007/978-3-030-16481-2_42
[6] Bahrani AA, Powell DK, Yu G, Johnson ES, Jicha GA, Smith CD. White matter hyperintensity associations with cerebral blood flow in elderly subjects stratified by cerebrovascular risk. J Stroke Cerebrovasc Dis. 2017;26(4):779–786. https://doi.org/10.1016/j.jstrokecerebrovasdis.2016.10.017
[7] Ishibashi M, Kimura N, Aso Y, Matsubara E. Effects of white matter lesions on brain perfusion in patients with mild cognitive impairment. Clin Neurol Neurosurg. 2018;168:7–11. https://doi.org/10.1016/j.clineuro.2018.02.030
[8] Stewart CR, Stringer MS, Shi Y, Thrippleton MJ, Wardlaw JM. Associations between white matter hyperintensity burden, cerebral blood flow and transit time in small vessel disease: an updated meta-analysis. Front Neurol. 2021;12:647848. https://doi.org/10.3389/fneur.2021.647848
[9] Crane DE, Black SE, Ganda A, Mikulis DJ, Nestor SM, Donahue MJ, et al. Gray matter blood flow and volume are reduced in association with white matter hyperintensity lesion burden: a cross-sectional MRI study. Front Aging Neurosci. 2015;7:131. https://doi.org/10.3389/fnagi.2015.00131
[10] O’Sullivan M, Lythgoe DJ, Pereira AC, Summers PE, Jarosz JM, Williams SC, et al. Patterns of cerebral blood flow reduction in patients with ischemic leukoaraiosis. Neurology. 2002;59(3):321–326. https://doi.org/10.1212/WNL.59.3.321
[11] Crane DE, Black SE, Ganda A, Mikulis DJ, Nestor SM, Donahue MJ, et al. Gray matter blood flow and volume are reduced in association with white matter hyperintensity lesion burden: a cross-sectional MRI study. Front Aging Neurosci. 2015;7:131. https://doi.org/10.3389/fnagi.2015.00131
[12] Kim CM, Alvarado RL, Stephens K, Wey HY, Wang DJJ, Leritz EC, et al. Associations between cerebral blood flow and structural and functional brain imaging measures in individuals with neuropsychologically defined mild cognitive impairment. Neurobiol Aging. 2020;86:64–74. https://doi.org/10.1016/j.neurobiolaging.2019.10.023
[13] Ten Dam VH, van den Heuvel DMJ, de Craen AJM, Bollen ELEM, Murray HM, Westendorp RGJ, et al. Decline in total cerebral blood flow is linked with increase in periventricular but not deep white matter hyperintensities. Radiology. 2007;243(1):198–203. https://doi.org/10.1148/radiol.2431052111
[14] Brickman AM, Zahra A, Muraskin J, Steffener J, Holland CM, Habeck C, et al. Reduction in cerebral blood flow in areas appearing as white matter hyperintensities on magnetic resonance imaging. Psychiatry Res Neuroimaging. 2009;172(2):117–120. https://doi.org/10.1016/j.pscychresns.2008.11.006
[15] Wardlaw JM, Doubal FN, Valdés-Hernández M, Wang X, Chappell FM, Shuler K, et al. Blood–brain barrier permeability and long-term clinical and imaging outcomes in cerebral small vessel disease. Stroke. 2013;44(2):525–527. https://doi.org/10.1161/STROKEAHA.112.669994
[16] Li Y, Li M, Zhang X, Shi Q, Yang S, Fan H, et al. Higher blood–brain barrier permeability is associated with higher white matter hyperintensities burden. J Neurol. 2017;264(7):1474–1481. https://doi.org/10.1007/s00415-017-8550-8
[17] Gupta N, Simpkins AN, Hitomi E, Dias C, Leigh R, NIH Natural History of Stroke Investigators. White matter hyperintensity-associated blood-brain barrier disruption and vascular risk factors. J Stroke Cerebrovasc Dis. 2018;27(2):466–471. https://doi.org/10.1016/j.jstrokecerebrovasdis.2017.09.026
[18] Feng M, Wen H, Xin H, Wang S, Gao Y, Sui C, et al. Decreased local specialization of brain structural networks associated with cognitive dysfunction revealed by probabilistic diffusion tractography for different cerebral small vessel disease burdens. Mol Neurobiol. 2024;61(1):326–339. https://doi.org/10.1007/s12035-023-03597-0
[19] Tuladhar AM, Tay J, van Leijsen EMC, Lawrence AJ, van Uden IWM, Bergkamp MI, et al. Structural network changes in cerebral small vessel disease. J Neurol Neurosurg Psychiatry. 2020;91(2):196–203. https://doi.org/10.1136/jnnp-2019-321767
[20] Wan S, Dandu C, Han G, Guo Y, Ding Y, Song H, et al. Plasma inflammatory biomarkers in cerebral small vessel disease: a review. CNS Neurosci Ther. 2023;29(2):498–515. https://doi.org/10.1111/cns.14047
[21] Boehme AK, McClure LA, Zhang Y, Luna JM, Del Brutto OH, Benavente OR, et al. Inflammatory markers and outcomes after lacunar stroke: levels of inflammatory markers in treatment of stroke study. Stroke. 2016;47(3):659–667. https://doi.org/10.1161/STROKEAHA.115.012166
[22] Zhong L, Chen XF, Wang T, Wang Z, Liao C, Wang Z, et al. Soluble TREM2 induces inflammatory responses and enhances microglial survival. J Exp Med. 2017;214(3):597–607. https://doi.org/10.1084/jem.20160844
[23] Yang J, Fu Z, Zhang X, Xiong M, Meng L, Zhang Z, et al. TREM2 ectodomain and its soluble form in Alzheimer's disease. J Neuroinflammation. 2020;17:204. https://doi.org/10.1186/s12974-020-01878-2
[24] Park SH, Lee EH, Kim HJ, Jo S, Lee S, Seo SW, et al. The relationship of soluble TREM2 to other biomarkers of sporadic Alzheimer's disease. Sci Rep. 2021;11:13050. https://doi.org/10.1038/s41598-021-92101-6
[25] Rauchmann BS, Schneider-Axmann T, Alexopoulos P, Perneczky R, Alzheimer's Disease Neuroimaging Initiative. CSF soluble TREM2 as a measure of immune response along the Alzheimer's disease continuum. Neurobiol Aging. 2019;74:182–190. https://doi.org/10.1016/j.neurobiolaging.2018.10.022
[26] Rachmian N, Medina S, Cherqui U, Akiva H, Deitch D, Edilbi D, et al. Identification of senescent, TREM2-expressing microglia in aging and Alzheimer's disease model mouse brain. Nat Neurosci. 2024;27(6):1116–1124. https://doi.org/10.1038/s41593-024-01620-8
[27] Tsai HH, Chen YF, Yen RF, Lo YL, Yang KC, Jeng JS, et al. Plasma soluble TREM2 is associated with white matter lesions independent of amyloid and tau. Brain. 2021;144(11):3371–3380. https://doi.org/10.1093/brain/awab332
[28] Kwon HS, Lee EH, Park HH, Jin JH, Choi H, Lee KY, et al. Early increment of soluble triggering receptor expressed on myeloid cells 2 in plasma might be a predictor of poor outcome after ischemic stroke. J Clin Neurosci. 2020;73:215–218. https://doi.org/10.1016/j.jocn.2020.02.016
[29] Wu C, Ma YH, Hu H, Zhao B, Tan L, Alzheimer's Disease Neuroimaging Initiative. Soluble TREM2, Alzheimer's disease pathology, and risk for progression of cerebral small vessel disease: a longitudinal study. J Alzheimers Dis. 2023;92(1):311–322. https://doi.org/10.3233/JAD-220731
[30] Ma LZ, Tan L, Bi YL, Shen XN, Xu W, Ma YH, et al. Dynamic changes of CSF sTREM2 in preclinical Alzheimer's disease: the CABLE study. Mol Neurodegener. 2020;15:25. https://doi.org/10.1186/s13024-020-00374-8
[31] van Lengerich B, Zhan L, Xia D, Chan D, Joy D, Park JI, et al. A TREM2-activating antibody with a blood–brain barrier transport vehicle enhances microglial metabolism in Alzheimer's disease models. Nat Neurosci. 2023;26(3):416–429. https://doi.org/10.1038/s41593-022-01240-0
[32] Ruganzu JB, Zheng Q, Wu X, He Y, Peng X, Jin H, et al. TREM2 overexpression rescues cognitive deficits in APP/PS1 transgenic mice by reducing neuroinflammation via the JAK/STAT/SOCS signaling pathway. Exp Neurol. 2021;336:113506. https://doi.org/10.1016/j.expneurol.2020.113506
[33] Su R, Zhou T. Alpha-synuclein induced immune cells activation and associated therapy in Parkinson’s disease. Front Aging Neurosci. 2021;13:769506. https://doi.org/10.3389/fnagi.2021.769506
[34] Zhang J, Liu Y, Zheng Y, Luo Y, Du Y, Zhao Y, et al. TREM-2-p38 MAPK signaling regulates neuroinflammation during chronic cerebral hypoperfusion combined with diabetes mellitus. J Neuroinflammation. 2020;17(1):2. https://doi.org/10.1186/s12974-019-1688-9
[35] Folstein MF, Anthony JC, Parhad I, Duffy B, Gruenberg EM. The meaning of cognitive impairment in the elderly. J Am Geriatr Soc. 1985;33(4):228–235. https://doi.org/10.1111/j.1532-5415.1985.tb07109.x
[36] Bergeron D, Flynn K, Verret L, Poulin S, Bouchard RW, Bocti C, et al. Multicenter validation of an MMSE‐MoCA conversion table. J Am Geriatr Soc. 2017;65(5):1067–1072. https://doi.org/10.1111/jgs.14779
[37] Putcha D, Brickhouse M, Wolk DA, Dickerson BC. Fractionating the Rey Auditory Verbal Learning Test: Distinct roles of large-scale cortical networks in prodromal Alzheimer's disease. Neuropsychologia. 2019;129:83–92. https://doi.org/10.1016/j.neuropsychologia.2019.03.015
[38] Scarpina F, Tagini S. The Stroop color and word test. Front Psychol. 2017;8:557. https://doi.org/10.3389/fpsyg.2017.00557
[39] Wei M, Shi J, Li T, Ni J, Zhang X, Li Y, et al. Diagnostic accuracy of the Chinese version of the Trail-Making Test for screening cognitive impairment. J Am Geriatr Soc. 2018;66(1):92–99. https://doi.org/10.1111/jgs.15135
[40] Leung JL, Lee GT, Lam Y, Chan RC, Wu JY. The use of the Digit Span Test in screening for cognitive impairment in acute medical inpatients. Int Psychogeriatr. 2011;23(10):1569–1574. https://doi.org/10.1017/S1041610211001167
[41] Liu S, Cao X, Wu Z, Deng S, Fu H, Wang Y, et al. TREM2 improves neurological dysfunction and attenuates neuroinflammation, TLR signaling and neuronal apoptosis in the acute phase of intracerebral hemorrhage. Front Aging Neurosci. 2022;14:967825. https://doi.org/10.3389/fnagi.2022.967825
[42] Ferrara SJ, Chaudhary P, DeBell MJ, Marracci G, Miller H, Calkins E, et al. TREM2 is thyroid hormone regulated making the TREM2 pathway druggable with ligands for thyroid hormone receptor. Cell Chem Biol. 2022;29(2):239–248.e4. https://doi.org/10.1016/j.chembiol.2021.11.005
[43] Song NN, Yu JY, Wang C, Wu XQ, Ma GZ, Yuan XY, et al. Research progress in the pathogenesis of cognitive dysfunction in white matter hyperintensities: A narrative review. J Integr Neurosci. 2025;24(2):24840. https://doi.org/10.31083/j.jin2402484
[44] Huang H, Song W, Wang P, Zhu Y, Zheng L, Shen C, et al. White matter hyperintensities: cerebral small-vessel diseases and white matter microstructural impairments. iRadiology. 2025;3(1):5–25. https://doi.org/10.1002/ird3.121
[45] Raz N, Yang Y, Dahle CL, Land S. Volume of white matter hyperintensities in healthy adults: contribution of age, vascular risk factors, and inflammation-related genetic variants. Biochim Biophys Acta Mol Basis Dis. 2012;1822(3):361–369. https://doi.org/10.1016/j.bbadis.2011.08.007
[46] Balistreri CR, Monastero R. Neuroinflammation and neurodegenerative diseases: how much do we still not know? Brain Sci. 2023;14(1):19. https://doi.org/10.3390/brainsci14010019
[47] Zhong Y, Huang L, Cai S, Zhang Y, von Deneen KM, Ren A, et al. Altered effective connectivity patterns of the default mode network in Alzheimer's disease: an fMRI study. Neurosci Lett. 2014;578:171–175. https://doi.org/10.1016/j.neulet.2014.06.043
[48] Sabayan B, Westendorp RG, van der Grond J, Stott DJ, Sattar N, van Osch MJ, et al. Markers of endothelial dysfunction and cerebral blood flow in older adults. Neurobiol Aging. 2014;35(2):373–377. https://doi.org/10.1016/j.neurobiolaging.2013.08.020
[49] Ashby JW, Mack JJ. Endothelial control of cerebral blood flow. Am J Pathol. 2021;191(11):1906–1916. https://doi.org/10.1016/j.ajpath.2021.02.023
[50] Ueno M, Tomimoto H, Akiguchi I, Wakita H, Sakamoto H. Blood–brain barrier disruption in white matter lesions in a rat model of chronic cerebral hypoperfusion. J Cereb Blood Flow Metab. 2002;22(1):97–104. https://doi.org/10.1097/00004647-200201000-00012
[51] Rosenberg GA. Inflammation and white matter damage in vascular cognitive impairment. Stroke. 2009;40(3 Suppl 1):S20–S23. https://doi.org/10.1161/STROKEAHA.108.533133
[52] Hainsworth AH, Minett T, Andoh J, Forster G, Bhide I, Barrick TR, et al. Neuropathology of white matter lesions, blood–brain barrier dysfunction, and dementia. Stroke. 2017;48(10):2799–2804. https://doi.org/10.1161/STROKEAHA.117.018101
[53] Glushakova OY, Johnson D, Hayes RL. Delayed increases in microvascular pathology after experimental traumatic brain injury are associated with prolonged inflammation, blood–brain barrier disruption, and progressive white matter damage. J Neurotrauma. 2014;31(13):1180–1193. https://doi.org/10.1089/neu.2013.3080
[54] Hamilton OKL, Backhouse EV, Janssen E, Jochems ACC, Maher C, Ritakari TE, et al. Cognitive impairment in sporadic cerebral small vessel disease: a systematic review and meta-analysis. Alzheimers Dement. 2021;17(4):665–685. https://doi.org/10.1002/alz.12221
[55] van Dinther M, Voorter PH, Zhang E, van Kuijk SM, Jansen JF, van Oostenbrugge RJ, et al. The neurovascular unit and its correlation with cognitive performance in patients with cerebral small vessel disease: a canonical correlation analysis approach. GeroScience. 2024;46(5):5061–5073. https://doi.org/10.1007/s11357-024-01235-8
[56] Harrison BJ, Shaw M, Yücel M, Purcell R, Brewer WJ, Strother SC, et al. Functional connectivity during Stroop task performance. Neuroimage. 2005;24(1):181–191. https://doi.org/10.1016/j.neuroimage.2004.08.033
[57] Belghali M, Statsenko Y, Laver V. Stroop switching card test: brief screening of executive functions across the lifespan. Aging Neuropsychol Cogn. 2022;29(1):14–33. https://doi.org/10.1080/13825585.2020.1844865
[58] Heyder K, Suchan B, Daum I. Cortico-subcortical contributions to executive control. Acta Psychol (Amst). 2004;115(2–3):271–289. https://doi.org/10.1016/j.actpsy.2003.12.010
[59] Elliott R. Executive functions and their disorders. Br Med Bull. 2003;65(1):49–59. https://doi.org/10.1093/bmb/65.1.49
[60] Jones DK, Leemans A. Diffusion tensor imaging. Methods Mol Biol. 2011;711:127–144. https://doi.org/10.1007/978-1-61737-992-5_6
[61] Alexander AL, Lee JE, Lazar M, Field AS. Diffusion tensor imaging of the brain. Neurotherapeutics. 2007;4(3):316–329. https://doi.org/10.1016/j.nurt.2007.05.011
Type
Published
Data Availability Statement
All data supporting the findings of this study are included in this published article.
Issue
Section
License
Copyright (c) 2025 Cell Conflux
This work is licensed under a Creative Commons Attribution 4.0 International License.
